| Zeeshan Sheriff, MD | |
|
789 Central Ave, Dover, NH 03820-2526 | |
| (603) 740-2503 | |
| Not Available |
| Full Name | Zeeshan Sheriff |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 12 Years |
| Location | 789 Central Ave, Dover, New Hampshire |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1326691700 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 22409 (New Hampshire) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Wentworth-douglass Hospital | Dover, NH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Wentworth Douglass Physician Corporation | 5496749848 | 372 |
News Archive
Chronic kidney disease (CKD) affects at least one in four Americans who are older than 60 and can significantly shorten lifespan. Yet the few available drugs for CKD can only modestly delay the disease's progress towards kidney failure. Now, however, a team led by researchers at the Perelman School of Medicine at the University of Pennsylvania, has found an aspect of CKD's development that points to a promising new therapeutic strategy.
When UC Santa Barbara neurology professor Kenneth S. Kosik was a newly minted graduate in 1972, with bachelor's and master's degrees in English literature from Case Western University, becoming one of the foremost authorities in the field of Alzheimer's research was probably nowhere on his radar. But that would soon change.
Cancer-causing human papillomaviruses diverged from their most recent common ancestors approximately half a million years ago, roughly coinciding with the timing of the split between archaic Neanderthals and modern Homo sapiens, according to a study published November 1 in the open-access journal PLOS Pathogens by Zigui Chen of the Chinese University of Hong Kong, Robert Burk of the Albert Einstein College of Medicine, and colleagues.
DNAe, the inventor of next generation semiconductor DNA sequencing technology and developer of a new, game-changing test for bloodstream infections, announces that its CBO, Nick McCooke presented an update on its first product, the LiDia bloodstream infections (BSI) test, and outlined DNAe's pipeline of genomic-based tests at BioCentury's 24th Annual Newsmakers in the Biotech Industry.
› Verified 4 days ago
| Entity Name | Wentworth Douglass Physician Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447352430 PECOS PAC ID: 5496749848 Enrollment ID: O20040409000433 |
News Archive
Chronic kidney disease (CKD) affects at least one in four Americans who are older than 60 and can significantly shorten lifespan. Yet the few available drugs for CKD can only modestly delay the disease's progress towards kidney failure. Now, however, a team led by researchers at the Perelman School of Medicine at the University of Pennsylvania, has found an aspect of CKD's development that points to a promising new therapeutic strategy.
When UC Santa Barbara neurology professor Kenneth S. Kosik was a newly minted graduate in 1972, with bachelor's and master's degrees in English literature from Case Western University, becoming one of the foremost authorities in the field of Alzheimer's research was probably nowhere on his radar. But that would soon change.
Cancer-causing human papillomaviruses diverged from their most recent common ancestors approximately half a million years ago, roughly coinciding with the timing of the split between archaic Neanderthals and modern Homo sapiens, according to a study published November 1 in the open-access journal PLOS Pathogens by Zigui Chen of the Chinese University of Hong Kong, Robert Burk of the Albert Einstein College of Medicine, and colleagues.
DNAe, the inventor of next generation semiconductor DNA sequencing technology and developer of a new, game-changing test for bloodstream infections, announces that its CBO, Nick McCooke presented an update on its first product, the LiDia bloodstream infections (BSI) test, and outlined DNAe's pipeline of genomic-based tests at BioCentury's 24th Annual Newsmakers in the Biotech Industry.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Zeeshan Sheriff, MD Po Box 412503, Boston, MA 02241-2503 Ph: (617) 726-3884 | Zeeshan Sheriff, MD 789 Central Ave, Dover, NH 03820-2526 Ph: (603) 740-2503 |
News Archive
Chronic kidney disease (CKD) affects at least one in four Americans who are older than 60 and can significantly shorten lifespan. Yet the few available drugs for CKD can only modestly delay the disease's progress towards kidney failure. Now, however, a team led by researchers at the Perelman School of Medicine at the University of Pennsylvania, has found an aspect of CKD's development that points to a promising new therapeutic strategy.
When UC Santa Barbara neurology professor Kenneth S. Kosik was a newly minted graduate in 1972, with bachelor's and master's degrees in English literature from Case Western University, becoming one of the foremost authorities in the field of Alzheimer's research was probably nowhere on his radar. But that would soon change.
Cancer-causing human papillomaviruses diverged from their most recent common ancestors approximately half a million years ago, roughly coinciding with the timing of the split between archaic Neanderthals and modern Homo sapiens, according to a study published November 1 in the open-access journal PLOS Pathogens by Zigui Chen of the Chinese University of Hong Kong, Robert Burk of the Albert Einstein College of Medicine, and colleagues.
DNAe, the inventor of next generation semiconductor DNA sequencing technology and developer of a new, game-changing test for bloodstream infections, announces that its CBO, Nick McCooke presented an update on its first product, the LiDia bloodstream infections (BSI) test, and outlined DNAe's pipeline of genomic-based tests at BioCentury's 24th Annual Newsmakers in the Biotech Industry.
› Verified 4 days ago
Magdalena Scherer, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 789 Central Ave, Dover, NH 03820 Phone: 603-740-2503 | |
Janaki S Fonseka, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 789 Central Ave, Level 2, Dover, NH 03820 Phone: 603-740-2503 Fax: 603-740-2497 | |
John J Novello, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 789 Central Avenue, Level 2, Dover, NH 03820 Phone: 603-740-2503 Fax: 603-740-2497 | |
Yulius Leonard Haryadi, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 10 Members Way Fl 5, Dover, NH 03820 Phone: 603-609-6800 Fax: 603-609-6820 | |
Utsav Nayan Parikh, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 789 Central Ave, Dover, NH 03820 Phone: 603-740-2503 | |
Linsley Sikorski, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 789 Central Ave, Dover, NH 03820 Phone: 603-740-2503 | |
Leo Rocero Uy, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 789 Central Ave, Dover, NH 03820 Phone: 603-740-2503 Fax: 603-740-2497 |